EU drugs regulator studying expanded use of Covid-19 drug remdesivir
Coronavirus chronicle
23 February, 2021, 03:30 pm
Last modified: 23 February, 2021, 03:47 pm
Europe had conditionally approved remdesivir, sold under the brand name Veklury, in July for treating Covid-19 in adults and adolescents with pneumonia requiring oxygen support
Photo: Collected
Europe's drugs regulator said on Tuesday it is evaluating the use of remdesivir in Covid-19 patients who do not need oxygen support, after developer Gilead Sciences submitted an application to extend the medicine's use.
Europe had conditionally approved remdesivir, sold under the brand name Veklury, in July for treating Covid-19 in adults and adolescents with pneumonia requiring oxygen support.
Comments
While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.